EP1902036B1 - Process for the preparation of rosuvastatin and intermediates - Google Patents
Process for the preparation of rosuvastatin and intermediates Download PDFInfo
- Publication number
- EP1902036B1 EP1902036B1 EP06744403A EP06744403A EP1902036B1 EP 1902036 B1 EP1902036 B1 EP 1902036B1 EP 06744403 A EP06744403 A EP 06744403A EP 06744403 A EP06744403 A EP 06744403A EP 1902036 B1 EP1902036 B1 EP 1902036B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- salt
- compound
- methyl
- formula iii
- reacting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 30
- 238000000034 method Methods 0.000 title claims abstract description 26
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 title claims abstract description 13
- 229960000672 rosuvastatin Drugs 0.000 title claims abstract description 12
- 239000000543 intermediate Substances 0.000 title description 5
- 150000003839 salts Chemical class 0.000 claims abstract description 45
- 150000001875 compounds Chemical class 0.000 claims abstract description 33
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical group CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 claims abstract description 15
- 150000007529 inorganic bases Chemical class 0.000 claims abstract description 15
- 150000007530 organic bases Chemical class 0.000 claims abstract description 15
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims abstract description 12
- 239000001110 calcium chloride Substances 0.000 claims abstract description 11
- 229960002713 calcium chloride Drugs 0.000 claims abstract description 11
- 235000011148 calcium chloride Nutrition 0.000 claims abstract description 11
- 229910001628 calcium chloride Inorganic materials 0.000 claims abstract description 11
- 230000007062 hydrolysis Effects 0.000 claims abstract description 5
- 238000006460 hydrolysis reaction Methods 0.000 claims abstract description 5
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 claims description 24
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 21
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 16
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 16
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 15
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- UFRRREYAQODGRN-MCBHFWOFSA-N 2-[(4r,6s)-6-[(e)-2-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-propan-2-ylpyrimidin-5-yl]ethenyl]-2,2-dimethyl-1,3-dioxan-4-yl]acetic acid Chemical compound C(\[C@H]1OC(C)(C)O[C@@H](CC(O)=O)C1)=C/C=1C(C(C)C)=NC(N(C)S(C)(=O)=O)=NC=1C1=CC=C(F)C=C1 UFRRREYAQODGRN-MCBHFWOFSA-N 0.000 claims description 12
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 claims description 12
- 229920002554 vinyl polymer Polymers 0.000 claims description 10
- 230000015572 biosynthetic process Effects 0.000 claims description 9
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 claims description 9
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 8
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 8
- 230000007935 neutral effect Effects 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 7
- RQEUFEKYXDPUSK-ZETCQYMHSA-N (1S)-1-phenylethanamine Chemical compound C[C@H](N)C1=CC=CC=C1 RQEUFEKYXDPUSK-ZETCQYMHSA-N 0.000 claims description 6
- LDDMACCNBZAMSG-BDVNFPICSA-N (2r,3r,4s,5r)-3,4,5,6-tetrahydroxy-2-(methylamino)hexanal Chemical compound CN[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO LDDMACCNBZAMSG-BDVNFPICSA-N 0.000 claims description 6
- 229940093499 ethyl acetate Drugs 0.000 claims description 6
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 claims description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 6
- 235000019439 ethyl acetate Nutrition 0.000 claims description 5
- 239000003960 organic solvent Substances 0.000 claims description 5
- 230000008030 elimination Effects 0.000 claims description 4
- 238000003379 elimination reaction Methods 0.000 claims description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 3
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 3
- 159000000003 magnesium salts Chemical class 0.000 claims description 2
- 125000001176 L-lysyl group Chemical class [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 claims 1
- 239000000243 solution Substances 0.000 description 20
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 239000002585 base Substances 0.000 description 13
- 238000002844 melting Methods 0.000 description 12
- 230000008018 melting Effects 0.000 description 12
- 239000011541 reaction mixture Substances 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- 239000000047 product Substances 0.000 description 8
- 239000007795 chemical reaction product Substances 0.000 description 7
- 159000000000 sodium salts Chemical class 0.000 description 7
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 6
- 125000000250 methylamino group Chemical class [H]N(*)C([H])([H])[H] 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
- 238000004821 distillation Methods 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 235000019766 L-Lysine Nutrition 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- 125000005907 alkyl ester group Chemical group 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- GAHCUVFTIFOTKX-NRFPMOEYSA-N 2-[(4r,6s)-6-[(e)-2-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-propan-2-ylpyrimidin-5-yl]ethenyl]-2,2-dimethyl-1,3-dioxan-4-yl]acetic acid;methanamine Chemical compound NC.C(\[C@H]1OC(C)(C)O[C@@H](CC(O)=O)C1)=C/C=1C(C(C)C)=NC(N(C)S(C)(=O)=O)=NC=1C1=CC=C(F)C=C1 GAHCUVFTIFOTKX-NRFPMOEYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
- 231100000647 material safety data sheet Toxicity 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- -1 (6-{(E)-2-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-pyrimidin-5-yl]-vinyl}-(4R,6S)-2,2-dimethyl-[1,3]dioxan-4-yl)-acetic acid-N-methyl-D-glucosamine salt Chemical compound 0.000 description 1
- HCQRTPSDEFPKCT-UHFFFAOYSA-N 2-(6-formyl-2,2-dimethyl-1,3-dioxan-4-yl)acetic acid Chemical compound CC1(C)OC(CC(O)=O)CC(C=O)O1 HCQRTPSDEFPKCT-UHFFFAOYSA-N 0.000 description 1
- IUHDGHSLZKZMCC-NRFPMOEYSA-N 2-[(4r,6s)-6-[(e)-2-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-propan-2-ylpyrimidin-5-yl]ethenyl]-2,2-dimethyl-1,3-dioxan-4-yl]acetic acid;2-(2-hydroxyethylamino)ethanol Chemical compound OCCNCCO.C(\[C@H]1OC(C)(C)O[C@@H](CC(O)=O)C1)=C/C=1C(C(C)C)=NC(N(C)S(C)(=O)=O)=NC=1C1=CC=C(F)C=C1 IUHDGHSLZKZMCC-NRFPMOEYSA-N 0.000 description 1
- GHRDVVMQMYGHDB-NRFPMOEYSA-N 2-[(4r,6s)-6-[(e)-2-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-propan-2-ylpyrimidin-5-yl]ethenyl]-2,2-dimethyl-1,3-dioxan-4-yl]acetic acid;phenylmethanamine Chemical compound NCC1=CC=CC=C1.C(\[C@H]1OC(C)(C)O[C@@H](CC(O)=O)C1)=C/C=1C(C(C)C)=NC(N(C)S(C)(=O)=O)=NC=1C1=CC=C(F)C=C1 GHRDVVMQMYGHDB-NRFPMOEYSA-N 0.000 description 1
- NQTWWXIJLOBVLC-QIIDTADFSA-N 2-[(4r,6s)-6-formyl-2,2-dimethyl-1,3-dioxan-4-yl]-3,3-dimethylbutanoic acid Chemical compound CC(C)(C)C(C(O)=O)[C@H]1C[C@@H](C=O)OC(C)(C)O1 NQTWWXIJLOBVLC-QIIDTADFSA-N 0.000 description 1
- TZZDAIKFAVBSSD-NRFPMOEYSA-N 2-aminoethanol;2-[(4r,6s)-6-[(e)-2-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-propan-2-ylpyrimidin-5-yl]ethenyl]-2,2-dimethyl-1,3-dioxan-4-yl]acetic acid Chemical compound NCCO.C(\[C@H]1OC(C)(C)O[C@@H](CC(O)=O)C1)=C/C=1C(C(C)C)=NC(N(C)S(C)(=O)=O)=NC=1C1=CC=C(F)C=C1 TZZDAIKFAVBSSD-NRFPMOEYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-M CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c(cc2)ccc2F)c1/C=C/[C@H](C[C@H](CC([O-])=O)O)O Chemical compound CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c(cc2)ccc2F)c1/C=C/[C@H](C[C@H](CC([O-])=O)O)O BPRHUIZQVSMCRT-VEUZHWNKSA-M 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical class [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- VWBYXJRDIQCSLW-UHFFFAOYSA-N O=[P](c1ccccc1)c1ccccc1 Chemical group O=[P](c1ccccc1)c1ccccc1 VWBYXJRDIQCSLW-UHFFFAOYSA-N 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- LLSDKQJKOVVTOJ-UHFFFAOYSA-L calcium chloride dihydrate Chemical compound O.O.[Cl-].[Cl-].[Ca+2] LLSDKQJKOVVTOJ-UHFFFAOYSA-L 0.000 description 1
- 229940052299 calcium chloride dihydrate Drugs 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000010931 ester hydrolysis Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- UMSHZKNXUGXHLI-SVKRATOZSA-N ethyl 2-[(4r,6s)-6-[(e)-2-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-propan-2-ylpyrimidin-5-yl]ethenyl]-2,2-dimethyl-1,3-dioxan-4-yl]acetate Chemical compound O1C(C)(C)O[C@@H](CC(=O)OCC)C[C@H]1\C=C\C1=C(C(C)C)N=C(N(C)S(C)(=O)=O)N=C1C1=CC=C(F)C=C1 UMSHZKNXUGXHLI-SVKRATOZSA-N 0.000 description 1
- SFKZOHLJKIADNS-UHFFFAOYSA-N ethyl acetate 2-(2-hydroxyethylamino)ethanol Chemical compound N(CCO)CCO.C(C)OC(C)=O SFKZOHLJKIADNS-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- OMVJFAVRNHDSLM-OKLSWEBGSA-N methyl 2-[(4r,6s)-6-[(e)-2-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-propan-2-ylpyrimidin-5-yl]ethenyl]-2,2-dimethyl-1,3-dioxan-4-yl]acetate Chemical compound O1C(C)(C)O[C@@H](CC(=O)OC)C[C@H]1\C=C\C1=C(C(C)C)N=C(N(C)S(C)(=O)=O)N=C1C1=CC=C(F)C=C1 OMVJFAVRNHDSLM-OKLSWEBGSA-N 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- CVRDGWDBQZPJJI-UHFFFAOYSA-N n-[5-(diphenylphosphorylmethyl)-4-(4-fluorophenyl)-6-propan-2-ylpyrimidin-2-yl]-n-methylmethanesulfonamide Chemical compound C=1C=CC=CC=1P(=O)(C=1C=CC=CC=1)CC=1C(C(C)C)=NC(N(C)S(C)(=O)=O)=NC=1C1=CC=C(F)C=C1 CVRDGWDBQZPJJI-UHFFFAOYSA-N 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 231100000462 teratogen Toxicity 0.000 description 1
- 239000003439 teratogenic agent Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Definitions
- the present invention relates to a new process for the preparation of a HMG-CoA reductase inhibitor rosuvastatin of formula I which comprises one of the following processes
- the further subject of the present invention is a compound of formula III and its salts formed by organic and inorganic base.
- Rosuvastatin (chemical name: (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-pyrimidin-5-yl]-3,5-dihydroxy-hept-6-anoic acid calcium salt) and its preparation process is described in European Patent EP 521471 .
- the active ingredient is prepared by the reduction of 7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R)-3-hydroxy-5-oxo-(E)-heptenoic acid and further steps of preparation. It is not a cost-effective preparation process because the 5S-hydroxy group of the side chain forming heptanoic acid is synthesized at the and of the preparation process, in one of the last steps.
- the sodium salt of the end product is prepared from BEM by the cleavage of the acetonide protecting group by acid hydrolysis using 0,02 M hydrochloric acid at 40 °C and by the cleavage of the tert-butyl protecting group using 1 M sodium hydroxide at 25 °C.
- the carboxylic acid is liberated from the sodium salt of rosuvastatin with hydrochloric acid (1 M) at -5 °C at a pH between 3. 4 and 4. 0.
- the methylamine salt is isolated from carboxylic acid with 40 % methylamine solution in water with a yield of 82 %.
- the methylamine salt is converted again to sodium salt with 8 % w/w aqueous sodium hydroxide solution and the methyl amine is eliminated with a complicated distillation process.
- the end product is prepared from the sodium salt by calcium chloride dihydrate. The application does not contain any data about the yield of the end product.
- the last part of the preparation -before the separation of the calcium salt- does not contain any possibility for the ideal purification.
- the first obtained sodium salt can not be purified and the methylamine salt prepared from the carboxylic acid can contaminate the product, because its elimination by distillation is difficult.
- Salts of the new compound of formula III can be prepared with high purity and a yield of 90 %. Salts formed from the compound of formula III with an organic or inorganic base can be prepared by a good yield an it can be easily purified. The crystalline nature of these salts ensures a pure end product, which is acknowledged as an important active ingredient in the pharmaceutical industry.
- the following bases can be used advantageously for the salt formation: methylamine, diethanolamine, ethanolamine, magnesium sulfate, L-lysine, benzylamine, L(-)- ⁇ -methyl-benzylamine or N-methyl-D-glucosamine. Especially preferred salts are diethanolamine, L-lysine and magnesium salts.
- the subject of the present invention is a process for the preparation of rosuvastatin of formula I which comprises one of the following processes
- the neutral organic solvent is preferably acetonitrile, ethyl-acetate or ethanol.
- the salt formation from compound of formula III is carried out with methylamine, diethanolamine, ethanolamine, magnesium sulfate, L-lysine, benzylamine, L(-)- ⁇ -methyl-benzylamine or N-methyl-D-glucosamine.
- the salt formation is carried out preferably with diethanolamine, L-lysine or magnesium sulfate.
- a further subject of the present invention is a compound of formula III and its salts formed by organic or inorganic base.
- a further subject of our invention is a salt of a compound of formula III formed by methylamine, diethanolamine, ethanolamine, magnesium sulfate, L-lysine, benzylamine, L(-)- ⁇ -methyl-benzylamine or N-methyl-D-glucosamine.
- Alkylesters of general formula II was prepared according to the process described in International Patent Application WO 00/49014 by the reaction of N-[5-[( diphenylphosphinoil)-methyl]-4-(4-fluorophenyl)-6-isopropyl-pyrimidin-2-yl]-N-methyl-methansulfonamide and 6-formyl-2,2-dimethyl-1,3-dioxan-4-yl-acetic acid in the presence of a strong base.
- the preparation of an acid of formula III can be carried out by the alkalic hydrolysis of alkylesters of formula II advantageously in tetrahydrofuran with 1M sodium hydroxide.
- a new salt is formed from the compound of formula III with organic or inorganic base in hydrous or anhydrous, neutral solvent.
- the salt formation is carried out preferably with methylamine, diethanolamine, ethanolamine, magnesium sulfate, L-lysine, benzylamine, L(-)- ⁇ -methyl-benzylamine or N-methyl-D-glucosamine.
- Salts formed from the a compound of formula III can be used for the preparation of calcium-E-7-[4-(4-fluorphenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihidroxihept-6-enoic acid.
- Acetonide protecting group was cleaved by heating of the above mentioned salts with 1 M hydrochloric acid solution at 80 °C and the filterable amorphous solid product can be prepared from a salt -formed with a strong base, preferably with alkali hydroxide- with calcium-chloride solution. After filtering and drying 90 % yield of the active ingredient was obtained.
- the main aspect of the present invention is the preparation of rosuvastatin preparing a new carboxylic acid of formula III from the alkyl ester of formula II and purifying by its salts, which were formed with organic or inorganic base.
- HMG-CoA reductase inhibitor rosuvastatin can be prepared from these salts with a yield of 90%.
- the advantage of the preparation process of the present invention contrary to the preparation process described in the International Patent Application WO 00/49014 is that methylamine salt is not used. Consequently the difficult elimination of methylamine by distillation has not to bee carried out.
- a further advantage is that the salt prepared from the base used for the salt formation does not contaminate the end product, because the acetonide protecting group is eliminated at the last step by hydrochloric acid (1 M) and the base is located in the aqueous phase as a hydrochloride salt.
- This preparation does not increases the number of steps of the process, in the contrary, it makes the process simpler because the base is eliminated by simple salt formation instead of distillation.
- the new salts prepared according to the invention can be purified easily. Contrary to the process described in International Patent Application WO 2004/108691 , wherein the purification of the amorphous end product can not be carried out, our process ensures the preparation of pure calcium-E-7-[4-(4-fluorphenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihidroxihept-6-enoic acid.
- N-[5-[(diphenylphosphinoyl)-methyl]-4-(4-fluorophenyl)-6-isopropyl-pyrimidindin-2-yl]-N-methyl-methanesulfonamide (6.4 g, 14.3 mmol) was dissolved in anhydrous tetrahydrofuran (105 ml) in a flask dried in vacuum at 120 °C in argon atmosphere and 3 g molecular sieve (Merck, 3 A) was added to the solution and it was cooled to -75-78 °C in the mixture of acetone and solid carbone dioxide.
- reaction mixture was stirred at -75 °C. for 1 hour and the resulted suspension was warmed up to -20 °C over 1 hour.
- the residue was solved in ethanol (30 ml) and the product was crystallized at +4 °C. The crystals were filtered and washed in cold ethanol (20 ml) and dried. Yield: 4.7 g (60%). Melting point: 191-3 °C.
- the reaction mixture was cooled to room temperature over 2 hours and the mixture was cooled in ice-cool water for another 2 hours, filtered and washed with cold acetonitrile (30 ml). The product was dried in vacuum at 40 °C. Yield: 4.9 g (85%). Melting point:151-153 °C.
- the reaction mixture was cooled to room temperature and ethyl acetate was added to the solution, then by stirring sodium hydroxide solution (2 M, 15 ml, 30 mmol) was added to the reaction mixture.
- the organic and aqueous phase was separated and the organic phase was extracted with brine (2x20 ml), and concentrated.
- the residue was dissolved in water (40 ml) and by stirring and cooling with ice-cool water an aqueous solution of calcium-chloride (1.62 g,11 mmol) in 20 ml water was added dropwise to the solution.
- the reaction mixture was stirred for 1 hour by cooling then it was stirred for 10-15 hours at room temperature.
- the precipitated product was filtered off and washed with ice-cool water (3x20 ml).
- the title product was dried in vacuum at 40 °C. Yield: 4.5 g (90%). Melting point: 150-180 °C, protracted.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
- Pyrane Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
Abstract
Description
-
- a.) reacting a compound of formula II
- b.) reacting a compound of formula III
- c.) reacting a salt of a compound of formula III
- The further subject of the present invention is a compound of formula III and its salts formed by organic and inorganic base.
- Rosuvastatin (chemical name: (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-pyrimidin-5-yl]-3,5-dihydroxy-hept-6-anoic acid calcium salt) and its preparation process is described in European Patent
EP 521471 - Another preparation process of rosuvastatin is described in International Patent Application
WO 00/49014 - According to the
WO 00/49014 - International Patent Application
WO 00/49014 - The disadvantage of the above mentioned process is the use of methylamine, which is unhealthy. The basic character and the volatility of methylamine induce its toxic, mucosa-destroying, mutagen and teratogen effects. (MSDS Data Sheet: http://physchem.ox.ac.uk/MSDS/; NCI Chem Carcinogenesis Res Info System: http://toxnet.nlm.nih.gov/ ; Schardein JL Chemically Induced Birth Defects 1993;2:842-69).
- The last part of the preparation -before the separation of the calcium salt- does not contain any possibility for the ideal purification. The first obtained sodium salt can not be purified and the methylamine salt prepared from the carboxylic acid can contaminate the product, because its elimination by distillation is difficult.
- The above mentioned disadvantages result the low yields, altogether 60-70 % of the preparation process described in
WO 00/49014 - International Patent Application
WO 2004/108691 relate to an alternative solution for the preparation of rosuvastatin using the BEM intermediate. The end product is obtained from the ester without the preparation of a salt of the intermediate. The difference compared to the preparation process described inWO 00/49014 - Considering to the above mentioned disadvantages our aim was to work out a new, simple process for preparing crystalline intermediates of high purity which enables to prepare rosuvastatin with a high purity and with significantly improved yields.
-
- Salts of the new compound of formula III can be prepared with high purity and a yield of 90 %. Salts formed from the compound of formula III with an organic or inorganic base can be prepared by a good yield an it can be easily purified. The crystalline nature of these salts ensures a pure end product, which is acknowledged as an important active ingredient in the pharmaceutical industry. The following bases can be used advantageously for the salt formation: methylamine, diethanolamine, ethanolamine, magnesium sulfate, L-lysine, benzylamine, L(-)-α-methyl-benzylamine or N-methyl-D-glucosamine. Especially preferred salts are diethanolamine, L-lysine and magnesium salts. These bases are knows salt-forming agents at the salt formation of other active ingredients, as well. (P.H.Stahl, C.G.Wermuth (Eds.) Handbook of Pharmaceutical Salts; Properties, Selection and Use, Wiley-VCH, 2002).
-
- b.) reacting a compound of formula II,
- b.) reacting a compound of formula III
- c.) reacting a salt of a compound of formula III
- In the preparation of compound of formula I the salt formation is carried out in a hydrous or anhydrous, neutral organic solvent.
- In the preparation of compound of formula I the neutral organic solvent is preferably acetonitrile, ethyl-acetate or ethanol.
- In the preparation of compound of formula I the salt formation from compound of formula III is carried out with methylamine, diethanolamine, ethanolamine, magnesium sulfate, L-lysine, benzylamine, L(-)-α-methyl-benzylamine or N-methyl-D-glucosamine.
- In the preparation of compound of formula I the salt formation is carried out preferably with diethanolamine, L-lysine or magnesium sulfate.
- In the preparation of compound of formula I the elimination of the acetonide group is carried out in neutral solvent in the presence of an acid.
- In the preparation of compound of formula I the neutral solvent is tetrahydrofuran.
-
- A further subject of our invention is a salt of a compound of formula III formed by methylamine, diethanolamine, ethanolamine, magnesium sulfate, L-lysine, benzylamine, L(-)-α-methyl-benzylamine or N-methyl-D-glucosamine.
- Other subjects of our invention are (6-{(E)-2-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-pyrimidin-5-yl]-vinyl}-(4R,6S)-2,2-dimethyl-[1,3]dioxan-4-yl)-acetic acid-diethanolamine salt, (6-{(E)-2-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methylamine)-pyrimidin-5-yl]-vinyl}-(4R,6S)-2,2-dimethyl-[1,3]dioxan-4-yl)-acetic acid-L-lysine salt and (6-{(E)-2-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methylamine)-pyrimidin-5-yl]-vinyl}-(4R,6S)-2,2-dimethyl-[1,3]dioxan-4-yl)-acetic acid-magnesium salt.
- Alkylesters of general formula II was prepared according to the process described in International Patent Application
WO 00/49014 - The preparation of an acid of formula III can be carried out by the alkalic hydrolysis of alkylesters of formula II advantageously in tetrahydrofuran with 1M sodium hydroxide.
- Thereafter a new salt is formed from the compound of formula III with organic or inorganic base in hydrous or anhydrous, neutral solvent. The salt formation is carried out preferably with methylamine, diethanolamine, ethanolamine, magnesium sulfate, L-lysine, benzylamine, L(-)-α-methyl-benzylamine or N-methyl-D-glucosamine.
- Salts formed from the a compound of formula III can be used for the preparation of calcium-E-7-[4-(4-fluorphenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihidroxihept-6-enoic acid. Acetonide protecting group was cleaved by heating of the above mentioned salts with 1 M hydrochloric acid solution at 80 °C and the filterable amorphous solid product can be prepared from a salt -formed with a strong base, preferably with alkali hydroxide- with calcium-chloride solution. After filtering and drying 90 % yield of the active ingredient was obtained.
- The main aspect of the present invention is the preparation of rosuvastatin preparing a new carboxylic acid of formula III from the alkyl ester of formula II and purifying by its salts, which were formed with organic or inorganic base. HMG-CoA reductase inhibitor rosuvastatin can be prepared from these salts with a yield of 90%.
- The advantage of the preparation process of the present invention contrary to the preparation process described in the International Patent Application
WO 00/49014 - The new salts prepared according to the invention can be purified easily. Contrary to the process described in International Patent Application
WO 2004/108691 , wherein the purification of the amorphous end product can not be carried out, our process ensures the preparation of pure calcium-E-7-[4-(4-fluorphenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihidroxihept-6-enoic acid. - N-[5-[(diphenylphosphinoyl)-methyl]-4-(4-fluorophenyl)-6-isopropyl-pyrimidindin-2-yl]-N-methyl-methanesulfonamide (6.4 g, 14.3 mmol) was dissolved in anhydrous tetrahydrofuran (105 ml) in a flask dried in vacuum at 120 °C in argon atmosphere and 3 g molecular sieve (Merck, 3 A) was added to the solution and it was cooled to -75-78 °C in the mixture of acetone and solid carbone dioxide. Sodium-bis-trimethylsilyl-amide (21.2 ml, 21.1 mmol, 1.0 M/THF) was added dropwise to the reaction mixture over 20 minutes. It was stirred and kept at the same temperature for 10 minutes then 6-formil-2,2-dimethyl-1,3-dioxan-4-yl-acetic acid-ethylester (4.1 g, 18 mmol) in toluol (83 ml) was added to the mixture over 20 minutes.
- The reaction mixture was stirred at -75 °C. for 1 hour and the resulted suspension was warmed up to -20 °C over 1 hour. The reaction mixture was added to water (50 ml) in extraction funnel and the flask was washed with toluol-THF mixture (50 ml, ratio= 1:1) and water then it was extracted twice with brine (2 x 50 ml). The residue was solved in ethanol (30 ml) and the product was crystallized at +4 °C. The crystals were filtered and washed in cold ethanol (20 ml) and dried.
Yield: 4.7 g (60%).
Melting point: 191-3 °C. - (6-{(E)-2-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-pyrimidin-5-yl]-vinyl}-(4R,6S)-2,2-dimetyl-[1,3]dioxan-4-yl)-acetic acid-methylester was prepared according to the method described above in example 1 with the difference that after adding dropwise sodium-bis-trimethylsilil-amide to the parent material 6-formil-2,2-dimethyl-1,3-dioxan-4-yl-acetic acid-methylester was added to the solution.
Yield: 4.8 g (63 %)
Melting point: 130-132 °C - (6-{(E)-2-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-pyrimidin-5-yl]-vinyl}-(4R,6S)-2,2-dimethyl-[1,3]dioxane-4-yl)-acetic acid ethylester (5.52g, 10 mmol) was dissolved in tetrahydrofuran (10 ml) and 1M sodium hydroxide 30 ml, 30 mmol) was added to the solution by stirring and it was heated to 90-100 °C. The reaction mixture was kept at this temperature until the parent material is transformed (ca. 4-6 hours). (It was analyzed by thin layer chromatography on silica gel in toluol-ethyl acetate (6:1)).
- The reaction mixture was diluted with ethyl-acetate (50 ml), the aqueous phase was separated and the organic phase was extracted with water (20 ml) then the organic phase was concentrated in vacuum. Water (100 ml) was added to the residue and the solution was treated with 1 M hydrogen chloride solution by cooling with ice-cold water. The precipitated product was filtered off, washed with cold water (2x 50 ml) and dried at 50 °C.
Yield: 4.9 g (95%)
Melting point: 172-174 °C - (6-{(E)-2-[4-(4-fluorphenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-pyrimidin-5-yl]-vinyl}-(4R,6S)-2,2-dimethyl-[1,3]dioxan-4-yl)-acetic acid (4.9 g, 9.4 mmol) prepared according to the method described in example 2 was dissolved in acetonitrile and methylamine (1.7 ml, 25 mmol) in 1 M ethanol was added to the solution and it was heated to 80-90 °C and kept at this temperature for 30 minutes. Then the reaction mixture was stirred at room temperature for 10-16 hours and the product was filtered and washed with cold acetonitrile (30 ml) and dried.
Yield: 4.7 g (85%).
Melting point: 190-192°C. - (6-{(E)-2-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-pyrimidin-5-yl]-vinyl}-(4R,6S)-2,2-dimethyl-[1,3]dioxan-4-yl)-acetic acid- was prepared according to the method described in example 2.
- To the solution of (6-{(E)-2-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-pyrimidin-5-yl]-vinyl}-(4R,6S)-2,2-dimethyl-[1,3]dioxan-4-yl)-acetic acid (4.9 g, 9.4 mmol) with ethyl-acetate diethanolamine (1.6 ml, 17 mmol) was added dropwise at 80 °C. The reaction mixture was stirred for 10-16 hours at room temperature, and the precipitate was filtered, washed with cold ethyl acetate (30 ml) and dried at room temperature.
Yield: 4.7 g (75%).
Melting point:151-3 °C. - A (6-{(E)-2-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-pyrimidin-5-yl]-vinyl}-(4R,6S)-2,2-dimethyl-[1,3]dioxan-4-yl)-acetic acid- was prepared according to the method described in example 2.
- A solution of (6-{(E)-2-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-pyrimidin-5-yl]-vinyl}-(4R,6S)-2,2-dimethyl-[1,3]dioxan-4-yl)-acetic acid (4.9 g, 9.4 mmol) and acetonitrile (110 ml) was heated to 70 °C and 1,1 equivalent ethanolamine was added dropwise to the solution then it was cooled to 50 °C and kept at this temperature for 120 minutes. The reaction mixture was cooled to room temperature over 2 hours and the mixture was cooled in ice-cool water for another 2 hours, filtered and washed with cold acetonitrile (30 ml). The product was dried in vacuum at 40 °C.
Yield: 4.9 g (85%).
Melting point:151-153 °C. - A (6-{(E)-2-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-pyrimidin-5-yl]-vinyl}-(4R,6S)-2,2-dimethyl-[1,3]dioxan-4-yl)-acetic acid was prepared according to the method described in example 2.
- A solution of (6-{(E)-2-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-pyrimidin-5-yl]-vinyl}-(4R,6S)-2,2-dimethyl-[1,3]dioxan-4-yl)-acetic acid (4.9 g, 9.4 mmol) and acetonitrile was concentrated and the residue was dissolved in water (80 ml). Sodium hydroxide (10 ml, 1 M) was added to the solution and a solution of magnesium sulfate dehydrate (1,4 g, 12 mmol) in water (5 ml) was added dropwise to the reaction mixture. It was stirred for 10-16 hours at room temperature, filtered, washed twice with icy water (2x30 ml) and dried.
Yield: 4.8 g (90%).
Melting point: 175-182 °C. - (6-{(E)-2-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-pyrimidin-5-yl]-vinyl}-(4R,6S)-2,2-dimethyl-[1,3]dioxan-4-yl)-acetic acid was prepared according to the method described in example 2.
- A solution of (6-{(E)-2-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-pyrimidin-5-yl]-vinyl}-(4R,6S)-2,2-dimethyl-[1,3]dioxan-4-yl)-acetic acid (4.9 g, 9.4 mmol) in 80 % ethanol-water 1,1 equivalent L-lysine was added dropwise and the product was filtered, washed with ethanol and dried.
Yield: 4.0 g (60%).
Melting point: 205-208 °C. - The following salt were prepared according to the method described in examples 3-7.
- Yield: 89%;
Melting point: 171-173 °C - Yield: 84% ;
Melting point: 200-202 °C - Yield: 75%;
Melting point: 170-172 °C - (6-{(E)-2-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-pyrimidin-5-yl]-vinyl}-(4R,6S)-2,2-dimethyl-[1,3]dioxan-4-yl)-acetic acid -methylamine salt (5.52g, 10 mmol) prepared according to the method described in example 3 was suspended in tetrahydrofuran (150 ml) and by stirring hydrochloric acid (1 M, 20 ml, 20 mmol) was added to the suspension and the mixture was heated to 80 °C. Heating was carried out until the parent material was totally transformed (20-30 minutes). (It was analyzed by thin layer chromatography on silica gel in chloroform-methanol (10:1)).
- The reaction mixture was cooled to room temperature and ethyl acetate was added to the solution, then by stirring sodium hydroxide solution (2 M, 15 ml, 30 mmol) was added to the reaction mixture. The organic and aqueous phase was separated and the organic phase was extracted with brine (2x20 ml), and concentrated. The residue was dissolved in water (40 ml) and by stirring and cooling with ice-cool water an aqueous solution of calcium-chloride (1.62 g,11 mmol) in 20 ml water was added dropwise to the solution. The reaction mixture was stirred for 1 hour by cooling then it was stirred for 10-15 hours at room temperature. The precipitated product was filtered off and washed with ice-cool water (3x20 ml). The title product was dried in vacuum at 40 °C.
Yield: 4.5 g (90%).
Melting point: 150-180 °C, protracted.
Claims (8)
- A process for the preparation of rosuvastatin of formula Ia.) reacting a compound of formula II,b.) reacting a compound of formula III
- A process according to claims 1, wherein the salt formation is carried out with methylamine, diethanolamine, ethanolamine, magnesium sulfate, L-lysine, benzylamine, L(-)-α-methyl-benzylamine or N-methyl-D-glucosamine in a neutral organic solvent,
wherein said neutral organic solvent is acetonitrile, ethyl-acetate, ethanol or tetrahydrofuran. - A process according to claims 1-2, wherein the elimination of the acetonide group is carried out in said neutral organic solvent in the presence of an acid.
- A salt of a compound of formula III according to claim 4, wherein the salt is formed by methylamine, diethanolamine, ethanolamine, magnesium sulfate, L-lysine, benzylamine, L(-)-α-methyl-benzylamine or N-methyl-D-glucosamine.
- A salt of a compound of formula III according to claim 4, which is diethanolamine salt of the (6-{(E)-2-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-pyrimidin-5-yl]-vinyl}-(4R,6S)-2,2-dimethyl-[1,3]dioxan-4-yl)-acetic acid.
- A salt of a compound of formula III according to claim 4, which is L-lysine salt of the (6-{(E)-2-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methylamine)-pyrimidin-5-yl]-vinyl}-(4R,6S)-2,2-dimethyl-[1,3]dioxan-4-yl)-acetic acid.
- A salt of a compound of formula III according to claim 4, which is magnesium salt of the (6-{(E)-2-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methylamine)-pyrimidin-5-yl]-vinyl}-(4R,6S)-2,2-dimethyl-[1,3]dioxan-4-yl)-acetic acid.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL06744403T PL1902036T3 (en) | 2005-05-26 | 2006-05-26 | Process for the preparation of rosuvastatin and intermediates |
SI200630623T SI1902036T1 (en) | 2005-05-26 | 2006-05-26 | Process for the preparation of rosuvastatin and intermediates |
MEP-2010-158A ME01781B (en) | 2005-05-26 | 2006-05-26 | Process for the preparation of rosuvastatin |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU0500537A HU227120B1 (en) | 2005-05-26 | 2005-05-26 | Process for the preparation of calcium salt of rosuvastatin via new intermediates |
PCT/HU2006/000049 WO2006126035A2 (en) | 2005-05-26 | 2006-05-26 | Process for the preparation of rosuvastatin |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1902036A2 EP1902036A2 (en) | 2008-03-26 |
EP1902036B1 true EP1902036B1 (en) | 2010-03-24 |
Family
ID=89986052
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP06744403A Active EP1902036B1 (en) | 2005-05-26 | 2006-05-26 | Process for the preparation of rosuvastatin and intermediates |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP1902036B1 (en) |
AT (1) | ATE461924T1 (en) |
DE (1) | DE602006013136D1 (en) |
DK (1) | DK1902036T3 (en) |
EA (1) | EA013304B1 (en) |
ES (1) | ES2342788T3 (en) |
HR (1) | HRP20100290T1 (en) |
HU (1) | HU227120B1 (en) |
ME (1) | ME01781B (en) |
PL (1) | PL1902036T3 (en) |
RS (1) | RS51205B (en) |
SI (1) | SI1902036T1 (en) |
WO (1) | WO2006126035A2 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20080060284A (en) | 2006-09-18 | 2008-07-01 | 테바 파마슈티컬 인더스트리즈 리미티드 | Crystalline rosuvastatin calcium |
WO2009157014A2 (en) * | 2008-01-30 | 2009-12-30 | Cadila Healthcare Limited | A process for preparing hmg-coa reductase inhibitors and intermediates |
CN102186843A (en) * | 2008-09-09 | 2011-09-14 | 拜康有限公司 | A process for preparation of rosuvastatin acetonide calcium |
BRPI1005147A2 (en) | 2009-01-15 | 2019-09-24 | Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag | rosuvastatin salt preparation process |
WO2011104725A2 (en) | 2010-02-23 | 2011-09-01 | Cadila Healthcare Limited | Hmg-coa reductase inhibitors and process for the preparation thereof |
WO2012038785A1 (en) * | 2010-09-21 | 2012-03-29 | Biocon Limited | Polymorphs of rosuvastatin acetonide calcium ((3r,5s,6e)-7-[4-(4- fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-pyrimn)in-5- yl)vinyl)-2,2-dimethyl-l,3-dioxan-4-yl) acetic acid calcium salt |
MX2010011006A (en) * | 2010-10-06 | 2012-04-18 | Senosiain S A De C V Lab | New salt of a pyrimidin derivative. |
WO2012073256A1 (en) * | 2010-11-29 | 2012-06-07 | Cadila Healthcare Limited | Salts of rosuvastatin |
CN102358747B (en) * | 2011-08-30 | 2012-09-19 | 浙江宏元药业有限公司 | Rosuvastatin calcium intermediate and method for preparing rosuvastatin calcium intermediate and rosuvastatin calcium |
CN102796036B (en) * | 2012-09-12 | 2014-06-04 | 江苏阿尔法药业有限公司 | Preparation method of atorvastatin calcium |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9903472D0 (en) * | 1999-02-17 | 1999-04-07 | Zeneca Ltd | Chemical process |
GB0011163D0 (en) * | 2000-05-10 | 2000-06-28 | Astrazeneca Ab | Chemical compound |
GB0324791D0 (en) * | 2003-10-24 | 2003-11-26 | Astrazeneca Ab | Chemical process |
-
2005
- 2005-05-26 HU HU0500537A patent/HU227120B1/en unknown
-
2006
- 2006-05-26 PL PL06744403T patent/PL1902036T3/en unknown
- 2006-05-26 RS RSP-2010/0158A patent/RS51205B/en unknown
- 2006-05-26 DK DK06744403.4T patent/DK1902036T3/en active
- 2006-05-26 EA EA200702579A patent/EA013304B1/en unknown
- 2006-05-26 ME MEP-2010-158A patent/ME01781B/en unknown
- 2006-05-26 AT AT06744403T patent/ATE461924T1/en active
- 2006-05-26 SI SI200630623T patent/SI1902036T1/en unknown
- 2006-05-26 EP EP06744403A patent/EP1902036B1/en active Active
- 2006-05-26 WO PCT/HU2006/000049 patent/WO2006126035A2/en active Application Filing
- 2006-05-26 DE DE602006013136T patent/DE602006013136D1/en active Active
- 2006-05-26 ES ES06744403T patent/ES2342788T3/en active Active
-
2010
- 2010-05-24 HR HR20100290T patent/HRP20100290T1/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2006126035A3 (en) | 2007-06-14 |
PL1902036T3 (en) | 2010-08-31 |
EA013304B1 (en) | 2010-04-30 |
ME01781B (en) | 2010-12-31 |
EA200702579A1 (en) | 2008-04-28 |
HU227120B1 (en) | 2010-07-28 |
HUP0500537A2 (en) | 2007-05-02 |
DE602006013136D1 (en) | 2010-05-06 |
WO2006126035A2 (en) | 2006-11-30 |
ES2342788T3 (en) | 2010-07-14 |
HUP0500537A3 (en) | 2008-04-28 |
EP1902036A2 (en) | 2008-03-26 |
DK1902036T3 (en) | 2010-06-28 |
SI1902036T1 (en) | 2010-05-31 |
RS51205B (en) | 2010-12-31 |
HU0500537D0 (en) | 2005-08-29 |
ATE461924T1 (en) | 2010-04-15 |
HRP20100290T1 (en) | 2010-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1902036B1 (en) | Process for the preparation of rosuvastatin and intermediates | |
EP2024341B1 (en) | Novel process for statins and its pharmaceutically acceptable salts thereof | |
JP5146965B2 (en) | Method for preparing amorphous rosuvastatin calcium free of impurities | |
EP1633727B1 (en) | Improved production of the rosuvastatin calcium salt | |
WO2010089770A2 (en) | Improved process for the preparation of highly pure (3r,5s)-7-[2-cyclopropyl-4-(4-fluorophenyl) quinolin-3-yl]-3,5-dihydroxy-6(e)-heptenoic acid and pharmaceutically acceptable salts thereof | |
WO2005054207A1 (en) | Process for the preparation of pyrimidine derivatives | |
NZ513261A (en) | Process for the production of tert-butyl (E)-(6-[2-[4- (4-fluorophenyl)-6-isopropyl-2- [methyl(methylsulfonyl)amino]pyrimidin-5-yl]vinyl](4R,6S)- 2,2-dimethyl[1,3]dioxan-4-yl)acetate | |
JP2007509119A (en) | Rosuvastatin (E) -7-'4- (4-fluorophenyl) -6-isopropyl-2-'methyl (methylsulfonyl) amino! Pyrimidin-5-yl! Calcium salt of (3R, 5S) -3,5-dihydroxyhept-6-enoic acid and method for producing crystalline intermediates thereof | |
US8394956B2 (en) | Process for preparing pyrimidine propenaldehyde | |
US20100274014A1 (en) | Process for manufacturing rosuvastatin potassium and crystalline and amorphous forms thereof | |
JP2013543884A (en) | Manufacturing method for high-purity pharmaceutical intermediates | |
EP2646419B1 (en) | Method for preparing rosuvastatin salts | |
EP2086946A2 (en) | Rosuvastatin dehydroabietylamine salt | |
US20110295005A1 (en) | Process for preparing pyrimidine derivatives | |
KR20140017207A (en) | Rosuvastatin isopropyl amine salt, the preparation method thereof and the preparation method of rosuvastatin hemicalcium salt using the same | |
WO2015131405A1 (en) | Intermediate compound for preparing rosuvastatin calcium and method for preparing rosuvastatin calcium therefrom | |
JP6034888B2 (en) | Novel statin intermediate and method for producing pitavastatin, rosuvastatin, cerivastatin and fluvastatin using the same | |
US20130066074A1 (en) | Process for the preparation of propenal intermediate and derivatives thereof | |
JP2013529223A (en) | Process for producing intermediate of pitavastatin or a salt thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20071214 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: HR YU |
|
RAX | Requested extension states of the european patent have changed |
Extension state: HR Payment date: 20071214 Extension state: YU Payment date: 20071214 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: RICHTER GEDEON NYRT. |
|
RTI1 | Title (correction) |
Free format text: PROCESS FOR THE PREPARATION OF ROSUVASTATIN AND INTERMEDIATES |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: DONAT, ANDREA Inventor name: ERDELYI, PETER Inventor name: SZEMZOE, ATTILA Inventor name: SZOEKE, KATALIN Inventor name: VUKICS, KRISZTINA Inventor name: FISCHER, JANOS |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: HR YU |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REF | Corresponds to: |
Ref document number: 602006013136 Country of ref document: DE Date of ref document: 20100506 Kind code of ref document: P |
|
REG | Reference to a national code |
Ref country code: RO Ref legal event code: EPE |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: TUEP Ref document number: P20100290 Country of ref document: HR |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: T1PR Ref document number: P20100290 Country of ref document: HR |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: VDEP Effective date: 20100324 Ref country code: ES Ref legal event code: FG2A Ref document number: 2342788 Country of ref document: ES Kind code of ref document: T3 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100324 |
|
REG | Reference to a national code |
Ref country code: PL Ref legal event code: T3 |
|
REG | Reference to a national code |
Ref country code: SK Ref legal event code: T3 Ref document number: E 7358 Country of ref document: SK |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100324 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100625 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100324 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100724 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100531 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100726 |
|
26N | No opposition filed |
Effective date: 20101228 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100324 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100526 Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100925 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100324 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 11 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 12 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 13 |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: ODRP Ref document number: P20100290 Country of ref document: HR Payment date: 20190430 Year of fee payment: 14 |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: ODRP Ref document number: P20100290 Country of ref document: HR Payment date: 20200520 Year of fee payment: 15 |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: ODRP Ref document number: P20100290 Country of ref document: HR Payment date: 20210517 Year of fee payment: 16 |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: ODRP Ref document number: P20100290 Country of ref document: HR Payment date: 20220519 Year of fee payment: 17 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SK Payment date: 20220524 Year of fee payment: 17 Ref country code: RO Payment date: 20220513 Year of fee payment: 17 Ref country code: LT Payment date: 20220422 Year of fee payment: 17 Ref country code: IT Payment date: 20220524 Year of fee payment: 17 Ref country code: IE Payment date: 20220520 Year of fee payment: 17 Ref country code: GB Payment date: 20220519 Year of fee payment: 17 Ref country code: FR Payment date: 20220523 Year of fee payment: 17 Ref country code: EE Payment date: 20220518 Year of fee payment: 17 Ref country code: DK Payment date: 20220523 Year of fee payment: 17 Ref country code: DE Payment date: 20220519 Year of fee payment: 17 Ref country code: CZ Payment date: 20220524 Year of fee payment: 17 Ref country code: BG Payment date: 20220520 Year of fee payment: 17 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SI Payment date: 20220516 Year of fee payment: 17 Ref country code: PL Payment date: 20220516 Year of fee payment: 17 Ref country code: LV Payment date: 20220517 Year of fee payment: 17 Ref country code: CH Payment date: 20220519 Year of fee payment: 17 Ref country code: BE Payment date: 20220519 Year of fee payment: 17 Ref country code: AT Payment date: 20220523 Year of fee payment: 17 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20220725 Year of fee payment: 17 |
|
REG | Reference to a national code |
Ref country code: EE Ref legal event code: HC1A Ref document number: E004191 Country of ref document: EE |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230608 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 602006013136 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: PBON Ref document number: P20100290 Country of ref document: HR Effective date: 20230526 |
|
REG | Reference to a national code |
Ref country code: EE Ref legal event code: MM4A Ref document number: E004191 Country of ref document: EE Effective date: 20230531 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MM4D Effective date: 20230526 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: EBP Effective date: 20230531 |
|
REG | Reference to a national code |
Ref country code: SK Ref legal event code: MM4A Ref document number: E 7358 Country of ref document: SK Effective date: 20230526 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MM01 Ref document number: 461924 Country of ref document: AT Kind code of ref document: T Effective date: 20230526 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230526 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20230526 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20230531 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230526 Ref country code: SI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230527 Ref country code: RO Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230526 Ref country code: LV Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230526 Ref country code: LT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230526 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230531 Ref country code: EE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230531 Ref country code: CZ Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230526 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230531 Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230526 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
REG | Reference to a national code |
Ref country code: SI Ref legal event code: KO00 Effective date: 20240226 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230526 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230526 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230526 Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230531 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20231201 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230526 |